Evaluation of Some Biochemical Factors Associated with Rheumatoid Arthritis

Tabarak Siraj  Ibrahim; bushra hasan

doi:10.30526/38.3.3765

Authors

Tabarak Siraj Ibrahim Department of Chemistry, College of Science for Women, University of Baghdad, Baghdad, Iraq. https://orcid.org/0009-0009-4983-347X
Bushra Faris Hasan Department of Chemistry, College of Science for Women, University of Baghdad, Baghdad, Iraq. https://orcid.org/0000-0002-4766-6120

DOI:

https://doi.org/10.30526/38.3.3765

Keywords:

Matrix metalloproteinase-1, C-reactive protein, Lipid profile, Rheumatoid arthritis, Rheumatoid factor

Abstract

Rheumatoid arthritis (RA) is a systemic disease that causes chronic inflammation, primarily affecting the synovial joints in the hands and feet. Laboratory investigations, such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), lipid profile, and matrix metalloproteinase-1 (MMP-1), evaluate the body's inflammation level. Rheumatoid arthritis is generally progressive, causing fatigue and weakening of the muscle joints. Despite recent treatment improvements, there is no known cure for RA. The study aimed to find the role of chemokine MMP-1 as a biomarker in serum samples of 80 patients with RA and 40 healthy subjects. The mean of MMP-1 was significantly higher in patients with RA compared to the control group (MMP-1: 3.27 ± 0.10 ng/mL vs. 1.40 ± 0.11 ng/mL, respectively). The results demonstrated a statistically significant distinction between the two groups. The binary logistic regression analysis revealed that MMP-1 had a statistically significant association with the occurrence of RA. Additionally, it was shown that MMP-1 had an area under the curve of 0.939 in people diagnosed with RA. Both of these experiments provided evidence of this result. According to the findings of the study, there is a possibility that MMP-1 has a role in the pathogenesis of RA since it was shown that patients with RA had higher levels of serum MMP-1, CRP, ESR, and lipid profile when compared to the control group. In conclusion, serum MMP-1 serves as a reliable diagnostic marker, accurately distinguishing individuals with active RA from control subjects.

Author Biographies

Tabarak Siraj Ibrahim, Department of Chemistry, College of Science for Women, University of Baghdad, Baghdad, Iraq.

Department of Chemistry, College of Science for Women, University of Baghdad, Baghdad, Iraq.
Bushra Faris Hasan, Department of Chemistry, College of Science for Women, University of Baghdad, Baghdad, Iraq.

Department of Chemistry, College of Science for Women, University of Baghdad, Baghdad, Iraq.

References

1. Murakami K, Mimori T. Diagnosis and treatment of rheumatoid arthritis: Toward the best practice. The pathophysiology in rheumatoid arthritis. Clin Calcium. 2018;28(5):595–600. https://doi.org/clica1805595600

2. Shareef BH, Hasan BF. Status of zinc and selenium in Iraqi women with rheumatoid arthritis and secondary osteoporosis. Biochem Cell Arch. 2021;21(1):1185–1194. https://connectjournals.com/03896.2021.21.1185

3. Kaeley GS, Bakewell C, Deodhar A. The importance of ultrasound in identifying and differentiating patients with early inflammatory arthritis: A narrative review. Arthritis Res Ther. 2020;22(1):1. https://doi.org/10.1186/s13075-019-2050-4

4. Johnson KJ, Sanchez HN, Schoenbrunner N. Defining response to TNF-inhibitors in rheumatoid arthritis: The negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders. Clin Rheumatol. 2019;38(11):2967–2976. https://doi.org/10.1007/s10067-019-04684-1

5. Radu AF, Bungau SG. Management of rheumatoid arthritis: An overview. Cells. 2021;10(11):2857. https://doi.org/10.3390/cells10112857

6. Hamid MM, Hassan BF, Al-Hafidh AH, Muhi SA, Al-Hashemi MA. Study of nephroblastoma overexpressed protein (NOV/CCN3) as a biomarker in serum of Iraqi patients with rheumatoid arthritis. Pak J Med Health Sci. 2022;16(6):460. https://doi.org/10.53350/pjmhs22166460

7. AL-Atabi DA, Hasan BF, AL-Hafidh AH. Estimation of some immunological and biochemical in the patients with systemic lupus erythematosus in males and females in Baghdad. Med Leg Updat. 2020;20(3):972–978. https://doi.org/10.37506/mlu.v20i3.1529

8. Emery P, Salmon M. Early rheumatoid arthritis: Time to aim for remission? Ann Rheum Dis. 1995;54(12):944–947. https://doi.org/10.1136/ard.54.12.944

9. Finckh A. Early inflammatory arthritis versus rheumatoid arthritis. Curr Opin Rheumatol. 2009;21(2):118–123. https://doi.org/10.1097/BOR.0b013e3283235ac4

10. Ma J-D, Zhou J-J, Zheng D-H, Chen L-F, Mo Y-Q, Wei X, et al. Serum matrix metalloproteinase-3 as a noninvasive biomarker of histological synovitis for diagnosis of rheumatoid arthritis. Mediators Inflamm. 2014;2014:179284. https://doi.org/10.1155/2014/179284

11. Mulherin D, Fitzgerald O, Bresnihan B. Clinical improvement and radiological deterioration in rheumatoid arthritis: Evidence that the pathogenesis of synovial inflammation and articular erosion may differ. Rheumatology. 1996;35(12):1263–1268. https://doi.org/10.1093/rheumatology/35.12.1263

12. Tchetverikov I, Lohmander LS, Verzijl N, Huizinga TWJ, TeKoppele JM, Hanemaaijer R, et al. MMP protein and activity levels in synovial fluid from patients with joint injury, inflammatory arthritis, and osteoarthritis. Ann Rheum Dis. 2005;64(5):694–698. https://doi.org/10.1136/ard.2004.022434

13. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: Role in arthritis. Front Biosci. 2006;11:529–543. https://doi.org/10.2741/1817

14. Sultan NS, AL-Tai AF. Estimation of pentraxin-3 (PTX3) in rheumatoid arthritis male patients with (with and without) type II diabetes mellitus in Iraq. Ibn Al-Haitham J Pure Appl Sci. 2018;31(3):55–62. https://doi.org/10.30526/31.3.2010

15. Beckers C, Jeukens X, Ribbens C, André B, Marcelis S, Leclercq P, et al. 18F-FDG PET imaging of rheumatoid knee synovitis correlates with dynamic magnetic resonance and sonographic assessments as well as with the serum level of metalloproteinase-3. Eur J Nucl Med Mol Imaging. 2006;33(3):275–280. https://doi.org/10.1007/s00259-005-1952-3

16. Scherer S, de Souza TB, de Paoli J, Brenol CV, Xavier RM, Brenol JC, et al. Matrix metalloproteinase gene polymorphisms in patients with rheumatoid arthritis. Rheumatol Int. 2010;30(3):369–373. https://doi.org/10.1007/s00296-009-0974-8

17. Sundaramurthy S, Saravanabhavan C, Kshirsagar P. Prediction and classification of rheumatoid arthritis using ensemble machine learning approaches. In: Proc Int Conf Decision Aid Sci Appl (DASA). IEEE; 2020. p. 17–21. https://doi.org/10.1109/DASA51403.2020.9317253

18. Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: A meta-analysis based on a systematic review. Rheumatol Int. 2021;41(5):863–877. https://doi.org/10.1007/s00296-020-04731-0

19. Hamid MM, Hassan BF, Al-Hafidh AH, Muhi SA. Study of pentraxin 3 protein (PTX3) as a biomarker in the serum of Iraqi patients with rheumatoid arthritis. NeuroQuantology. 2022;20:145–152. https://doi.org/10.14704/nq.2022.20.7.NQ33017

20. Itoh Y. Metalloproteinases: Potential therapeutic targets for rheumatoid arthritis. Endocr Metab Immune Disord Drug Targets. 2015;15(3):216–222. https://doi.org/10.2174/1871530315666150316122335

21. Araki Y, Mimura T. Matrix metalloproteinase gene activation resulting from disordered epigenetic mechanisms in rheumatoid arthritis. Int J Mol Sci. 2017;18(5):905. https://doi.org/10.3390/ijms18050905

22. Huang T-L, Mu N, Gu J-T, Shu Z, Zhang K, Zhao J-K, et al. DDR2-CYR61-MMP1 signaling pathway promotes bone erosion in rheumatoid arthritis through regulating migration and invasion of fibroblast-like synoviocytes. J Bone Miner Res. 2019;34(4):779–780. https://doi.org/10.1002/jbmr.3688

23. Chen Z, Wang H, Xia Y, Yan F, Lu Y. Therapeutic potential of mesenchymal cell–derived miRNA-150-5p–expressing exosomes in rheumatoid arthritis mediated by the modulation of MMP14 and VEGF. J Immunol. 2018;201(8):2472–2482. https://doi.org/10.4049/jimmunol.1800304

24. Zhang B, Jiang W. IL-1β, IL-17A, CRP and biologics history might serve as potential markers for clinical response to etanercept in rheumatoid arthritis patients. Inflammopharmacology. 2019;27(6):1123–1130. https://doi.org/10.1007/s10787-019-00624-2

25. Alwan IT, Ghali KH. Association risk of matrix metalloproteinase enzymes levels (MMP-1, MMP-9 and MMP-13) with development of rheumatoid arthritis. Ann Rom Soc Cell Biol. 2021;25(4):11369–11378. http://www.annalsofrscb.ro/index.php/journal/article/view/3915

26. Yu Z, Wang Y, Li Y, Liao C, Dai J, Luo Y, et al. Effect of moxibustion on the serum levels of MMP-1, MMP-3, and VEGF in patients with rheumatoid arthritis. Evid Based Complement Alternat Med. 2020;2020:7150605. https://doi.org/10.1155/2020/7150605

27. Taha AAA, Khadr NA, Elneily DAE, Elkhalifa MSA, Mohamad SSM. Serum matrix metalloproteinase-3 in patients with psoriasis with and without arthritis. J Egypt Womens Dermatol Soc. 2023;20(2):125–130. https://doi.org/10.4103/jewd.jewd_5_23

28. Abd-Allah SH, Shalaby SM, Pasha HF, El-Shal AS, Abou El-Saoud AM. Variation of matrix metalloproteinase 1 and 3 haplotypes and their serum levels in patients with rheumatoid arthritis and osteoarthritis. Genet Test Mol Biomarkers. 2012;16(1):15–20. https://doi.org/10.1089/gtmb.2011.0003

29. Kasher M, Cherny SS, Livshits G, Group CIW. Exploring potential shared genetic influences between rheumatoid arthritis and blood lipid levels. Atherosclerosis. 2022;363:48–56. https://doi.org/10.1016/j.atherosclerosis.2022.11.006

30. Alghamdi M, Alamry SA, Bahlas SM, Uversky VN, Redwan EM. Circulating extracellular vesicles and rheumatoid arthritis: A proteomic analysis. Cell Mol Life Sci. 2022;79(1):25. https://doi.org/10.1007/s00018-021-04020-4

31. Jabbar EAK, Al-Rumaidh SZ, Jouda J. Estimation of some biomarkers and cholesterol/HDL ratio to predict the risk of cardiovascular disease in rheumatoid arthritis. Ibn Al-Haitham J Pure Appl Sci. 2021;2021:23–28. https://doi.org/10.30526/2021.IHICPAS.2646

32. Dursunoğlu D, Evrengül H, Polat B, Tanrıverdi H, Çobankara V, Kaftan A, et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: Serum levels and relationship to inflammation. Rheumatol Int. 2005;25(4):241–245. https://doi.org/10.1007/s00296-004-0438-0

33. Oleiwi AR, Zgair AK. Estimation levels of CTHRC1 and some cytokines in Iraqi patients with rheumatoid arthritis. Baghdad Sci J. 2023;20(3):928–936. https://doi.org/10.21123/bsj.2023.8036

34. Khadim RM, Al-Fartusie FS. Evaluation of liver function and lipid profiles in Iraqi patients with rheumatoid arthritis. J Phys Conf Ser. 2021;1853. https://doi.org/10.1088/1742-6596/1853/1/012040